<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826421</url>
  </required_header>
  <id_info>
    <org_study_id>ILN296-P001</org_study_id>
    <nct_id>NCT02826421</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of Corneal Incision Size After Intraocular Lens (IOL) Implantation</brief_title>
  <official_title>Clinical Investigation of Corneal Incision Size After IOL Implantation With Preloaded Delivery Devices and a Manual Delivery Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare corneal incision size after IOL implantation with the
      use of one of four IOL delivery systems (three preloaded IOL delivery systems and one
      manually loaded IOL delivery system).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2016</start_date>
  <completion_date type="Actual">November 29, 2016</completion_date>
  <primary_completion_date type="Actual">November 29, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Corneal Incision Size After IOL Implantation (UltraSert, iTec, and iSert)</measure>
    <time_frame>Day 0, operative day</time_frame>
    <description>Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm). Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation. This endpoint was prespecified for the UltraSert, iTec, and iSert preloaded delivery systems. Only one eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Corneal Incision Size After IOL Implantation (UltraSert and Monarch III D)</measure>
    <time_frame>Day 0, operative day</time_frame>
    <description>Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm). Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation. This endpoint was prespecified for the UltraSert preloaded delivery system and the Monarch III D delivery system. Only one eye (study eye) contributed to the analysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>UltraSert Preloaded Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iTec Preloaded Delivery System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iSert Preloaded Delivery System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monarch III D Manual IOL Delivery System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UltraSert Preloaded Delivery System</intervention_name>
    <description>Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject</description>
    <arm_group_label>UltraSert Preloaded Delivery System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTec Preloaded Delivery System</intervention_name>
    <description>Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject</description>
    <arm_group_label>iTec Preloaded Delivery System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iSert Preloaded Delivery System</intervention_name>
    <description>Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject</description>
    <arm_group_label>iSert Preloaded Delivery System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monarch III D Manual IOL Delivery System</intervention_name>
    <description>Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject</description>
    <arm_group_label>Monarch III D Manual IOL Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to comprehend and sign a statement of informed consent;

          -  Willing and able to complete all required postoperative visits;

          -  Cataract;

          -  Planned cataract removal by phacoemulsification;

          -  Calculated lens power from 18.0 through 27.0 D inclusive;

          -  Preoperative astigmatism &lt;1.0D;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Systemic disease that affects the cornea;

          -  Any inflammation or edema of the cornea;

          -  Previous or planned refractive or corneal surgery during the subject's participation
             in the study;

          -  Previous corneal transplant;

          -  Previous retinal detachment;

          -  Pregnancy or lactation, current or planned, during the course of the study;

          -  Current participation in another investigational drug or device study that may
             confound the results of this investigation;

          -  Any condition observed before or during surgery that in the surgeon's medical opinion
             may affect the success of the cataract surgery;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Manager, GCRA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <results_first_submitted>June 30, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 4 study centers located in Spain and 2 study centers located in France.</recruitment_details>
      <pre_assignment_details>Of the 114 enrolled, 2 subjects did not meet inclusion/exclusion criteria, and 3 subjects were excluded prior to randomization for “other” reasons (ie, the maximum number of randomized subjects was reached). This reporting group includes all randomized subjects (109).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>UltraSert</title>
          <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="P2">
          <title>iTec</title>
          <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="P3">
          <title>iSert</title>
          <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="P4">
          <title>Monarch III D</title>
          <description>Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not given</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all randomized subjects whose cataract surgery procedure was completed (Full Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>UltraSert</title>
          <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="B2">
          <title>iTec</title>
          <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="B3">
          <title>iSert</title>
          <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="B4">
          <title>Monarch III D</title>
          <description>Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.4" spread="8.71"/>
                    <measurement group_id="B2" value="70.7" spread="8.31"/>
                    <measurement group_id="B3" value="73.0" spread="7.27"/>
                    <measurement group_id="B4" value="72.5" spread="7.10"/>
                    <measurement group_id="B5" value="71.9" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Corneal Incision Size After IOL Implantation (UltraSert, iTec, and iSert)</title>
        <description>Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm). Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation. This endpoint was prespecified for the UltraSert, iTec, and iSert preloaded delivery systems. Only one eye (study eye) contributed to the analysis.</description>
        <time_frame>Day 0, operative day</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>UltraSert</title>
            <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
          </group>
          <group group_id="O2">
            <title>iTec</title>
            <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
          </group>
          <group group_id="O3">
            <title>iSert</title>
            <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corneal Incision Size After IOL Implantation (UltraSert, iTec, and iSert)</title>
          <description>Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm). Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation. This endpoint was prespecified for the UltraSert, iTec, and iSert preloaded delivery systems. Only one eye (study eye) contributed to the analysis.</description>
          <population>Full Analysis Set</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.019"/>
                    <measurement group_id="O2" value="2.47" spread="0.016"/>
                    <measurement group_id="O3" value="2.54" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corneal Incision Size After IOL Implantation (UltraSert and Monarch III D)</title>
        <description>Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm). Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation. This endpoint was prespecified for the UltraSert preloaded delivery system and the Monarch III D delivery system. Only one eye (study eye) contributed to the analysis.</description>
        <time_frame>Day 0, operative day</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>UltraSert</title>
            <description>Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery</description>
          </group>
          <group group_id="O2">
            <title>Monarch III D</title>
            <description>Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corneal Incision Size After IOL Implantation (UltraSert and Monarch III D)</title>
          <description>Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm). Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation. This endpoint was prespecified for the UltraSert preloaded delivery system and the Monarch III D delivery system. Only one eye (study eye) contributed to the analysis.</description>
          <population>Full Analysis Set</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.019"/>
                    <measurement group_id="O2" value="2.49" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from time of consent for the duration of a subject’s participation in the study (up to 31 days). AEs are reported as pretreatment and treatment-emergent.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye combined.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pretreatment</title>
          <description>All subjects who consented to participate in the study prior to initiation of study treatment</description>
        </group>
        <group group_id="E2">
          <title>UltraSert</title>
          <description>All subjects treated with UltraSert</description>
        </group>
        <group group_id="E3">
          <title>iTec</title>
          <description>All subjects treated with iTec</description>
        </group>
        <group group_id="E4">
          <title>iSert</title>
          <description>All subjects treated with iSert</description>
        </group>
        <group group_id="E5">
          <title>Monarch III D</title>
          <description>All subjects treated with Monarch III D</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Surgical procedure repeated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr Global Brand Medical Affairs Lead, CDMA Surgical</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

